Omar K. Haffar, Ph.D.
Bret L. MacPherson, M.S.

Omar K. Haffar, Ph.D.: President, Chief Science Officer. Dr. Haffar is the scientific founder of ITI and has an extensive background in anti-viral research. After receiving his doctorate degree from the University of California, Berkeley, in 1985, Dr. Haffar joined the HIV-1 vaccine research group at Genentech Inc. (South San Francisco, CA). After two years Dr. Haffar joined the HIV-1 research group at Bristol-Myers Squibb (Seattle, WA), as a staff scientist. At Bristol-Myers Squibb Dr. Haffar directed research programs designed to identify novel vaccine candidates and to study the effect of the virus on the immune system.

In 1996, Dr. Haffar joined Cytokine Networks Inc. (Seattle, WA) as Vice President of Anti-Infective Research and Development. Dr. Haffar supervised the pre-clinical development of a novel class of anti-HIV-1 compounds that inhibit the nuclear transport of the HIV-1 genome during infection of target cells. This technology is currently licensed to International Therapeutics, Inc. Dr. Haffar is an inventor on patents describing these compounds and their application.

Bret L. MacPherson, M.S., Vice President of Operations. Mr. MacPherson brings diverse business and development experience to manage ITI’s day-to-day operations. For the past 11 years, he has worked primarily in clinical development, most recently as Director, Clinical Affairs at Cytokine PharmaSciences, Inc., the licensor of ITI’s core intellectual property. As such, Mr. MacPherson comes to ITI with a working knowledge of this anti-viral technology and experience developing similar compounds.

In 1986, Mr. MacPherson began his career in sales, training and marketing with SmithKline Beecham Pharmaceuticals. From SmithKline he moved on to Centocor, where his responsibilities shifted from the
commercialization effort to clinical development. Mr. MacPherson furthered his experience at Cell Therapeutics, a Seattle-based biotech concern. While at Cell Therapeutics, Mr. MacPherson managed clinical trials in oncology and inflammatory diseases.

Mr. MacPherson provides ITI with proven project management experience, especially with contract research organizations. He has participated in the submission of 4 IND applications and has worked on the development of 6 therapeutic drugs. Mr. MacPherson has Bachelor’s and Master’s of Science degrees from the University of Oregon.

Back to top